BioCentury | Jul 16, 2012
Company News

Galenea, Eisai deal

...Eisai and Galenea partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners...
...partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners will use Galenea's...
...term. Galenea will receive an undisclosed upfront payment and is eligible for undisclosed milestone payments. Galenea Corp....
BioCentury | Jul 10, 2012
Company News

Galenea, Eisai to develop synaptic modulators

...Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) and Galenea Corp. (Cambridge, Mass.) partnered to discover and develop synaptic modulators...
...partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners will use Galenea's...
...oversee development under the one-year deal, which includes an option to extend the deal's term. Galenea...
BioCentury | May 7, 2012
Financial News

Galenea completes venture financing

Galenea Corp. , Cambridge, Mass. Business: Neurology, Endocrine/Metabolic Date completed: 4/26/12 Type: Venture financing Raised: $6 million Investor: Stanley Medical Research Institute WIR Staff...
BioCentury | Sep 12, 2011
Company News

Galenea, CHDI Foundation deal

...Not-for-profit foundation CHDI and Galenea partnered to use Galenea's synaptic transmission drug discovery platform to identify...
...discovery platform to identify synaptic dysfunction associated with Huntington's disease (HD). The partnership will use Galenea's...
...synaptic dysfunctions in neurons derived from in vivo rodent models. The partners will also use Galenea's...
BioCentury | Dec 7, 2009
Company News

Galenea, Otsuka Pharmaceutical deal

...other CNS diseases. This is the second extension and brings the total committed funding for Galenea...
...resulting compounds, and Galena is eligible for milestones and royalties and retains a profit-sharing option. Galenea...
...candidate to Otsuka expected in 2010 (see BioCentury, Feb. 21, 2005 & Oct. 13, 2008). Galenea Corp....
BioCentury | Nov 3, 2008
Company News

Galenea, Organix Inc., Case Western Reserve University, University of North Carolina, Tufts University School of Medicine deal

...the universities will receive an undisclosed upfront payment and be eligible for milestones and royalties. Galenea Corp....
BioCentury | Oct 29, 2008
Company News

Galenea in-licenses 5-HT2C agonists

...the Tufts University School of Medicine and the University of North Carolina at Chapel Hill. Galenea...
BioCentury | Oct 13, 2008
Company News

Galenea, Otsuka Pharmaceutical deal

...lead optimization. The extension brings the total committed funding for Galenea to about $75 million. Galenea...
...and royalties or can exercise an option for profit sharing (see BioCentury, Feb. 21, 2005). Galenea Corp....
BioCentury | Jun 16, 2008
Strategy

Nastech slices and dices

...alpha in 2005; received rights to RNAi therapeutics against influenza and other respiratory infections from Galenea Corp....
...City of Hope National Medical Center , Duarte, Calif. Dicerna Pharmaceuticals Inc. , Boston, Mass. Galenea Corp....
BioCentury | Jun 16, 2008
Strategy

MDRNA chronicles

...worldwide rights to intranasal teriparatide ( PTH 1-34 ) to treat osteoporosis. I. 2/23/06 - Galenea...
Items per page:
1 - 10 of 16
BioCentury | Jul 16, 2012
Company News

Galenea, Eisai deal

...Eisai and Galenea partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners...
...partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners will use Galenea's...
...term. Galenea will receive an undisclosed upfront payment and is eligible for undisclosed milestone payments. Galenea Corp....
BioCentury | Jul 10, 2012
Company News

Galenea, Eisai to develop synaptic modulators

...Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) and Galenea Corp. (Cambridge, Mass.) partnered to discover and develop synaptic modulators...
...partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners will use Galenea's...
...oversee development under the one-year deal, which includes an option to extend the deal's term. Galenea...
BioCentury | May 7, 2012
Financial News

Galenea completes venture financing

Galenea Corp. , Cambridge, Mass. Business: Neurology, Endocrine/Metabolic Date completed: 4/26/12 Type: Venture financing Raised: $6 million Investor: Stanley Medical Research Institute WIR Staff...
BioCentury | Sep 12, 2011
Company News

Galenea, CHDI Foundation deal

...Not-for-profit foundation CHDI and Galenea partnered to use Galenea's synaptic transmission drug discovery platform to identify...
...discovery platform to identify synaptic dysfunction associated with Huntington's disease (HD). The partnership will use Galenea's...
...synaptic dysfunctions in neurons derived from in vivo rodent models. The partners will also use Galenea's...
BioCentury | Dec 7, 2009
Company News

Galenea, Otsuka Pharmaceutical deal

...other CNS diseases. This is the second extension and brings the total committed funding for Galenea...
...resulting compounds, and Galena is eligible for milestones and royalties and retains a profit-sharing option. Galenea...
...candidate to Otsuka expected in 2010 (see BioCentury, Feb. 21, 2005 & Oct. 13, 2008). Galenea Corp....
BioCentury | Nov 3, 2008
Company News

Galenea, Organix Inc., Case Western Reserve University, University of North Carolina, Tufts University School of Medicine deal

...the universities will receive an undisclosed upfront payment and be eligible for milestones and royalties. Galenea Corp....
BioCentury | Oct 29, 2008
Company News

Galenea in-licenses 5-HT2C agonists

...the Tufts University School of Medicine and the University of North Carolina at Chapel Hill. Galenea...
BioCentury | Oct 13, 2008
Company News

Galenea, Otsuka Pharmaceutical deal

...lead optimization. The extension brings the total committed funding for Galenea to about $75 million. Galenea...
...and royalties or can exercise an option for profit sharing (see BioCentury, Feb. 21, 2005). Galenea Corp....
BioCentury | Jun 16, 2008
Strategy

Nastech slices and dices

...alpha in 2005; received rights to RNAi therapeutics against influenza and other respiratory infections from Galenea Corp....
...City of Hope National Medical Center , Duarte, Calif. Dicerna Pharmaceuticals Inc. , Boston, Mass. Galenea Corp....
BioCentury | Jun 16, 2008
Strategy

MDRNA chronicles

...worldwide rights to intranasal teriparatide ( PTH 1-34 ) to treat osteoporosis. I. 2/23/06 - Galenea...
Items per page:
1 - 10 of 16